WHOOP has raised $575 million in fresh funding at a $10.1 billion valuation, as it accelerates its ambition to build a global platform for personalised, preventative healthcare powered by artificial intelligence and biometric data.
The Series G round was led by Collaborative Fund and drew participation from a broad mix of institutional investors, sovereign wealth funds and healthcare leaders, including Qatar Investment Authority and Mubadala Investment Company. Strategic backing also came from Abbott and Mayo Clinic, highlighting growing convergence between technology and traditional healthcare systems.
The round also attracted high-profile individual investors from the worlds of sport and entertainment, including Cristiano Ronaldo, LeBron James and Rory McIlroy, reflecting WHOOP’s strong association with elite performance and wellness.
The investment comes at a time when healthcare systems globally are under increasing strain from rising rates of chronic disease and ageing populations. WHOOP is positioning itself at the forefront of a shift from reactive treatment to preventative, data-driven health management.
Founder and chief executive Will Ahmed said the company is building a platform designed to help individuals monitor, understand and improve their health continuously.
“We are creating a personal health system that enables people to improve both their performance and long-term wellbeing,” he said.
At the core of the platform is continuous biometric monitoring, combined with AI models trained on more than 24 billion hours of physiological data. This allows WHOOP to deliver personalised insights into sleep, recovery, stress and physical performance, as well as early indicators of potential health risks.
WHOOP has experienced strong growth in recent years, with more than 2.5 million members globally and bookings rising 103 per cent in 2025 to reach a $1.1 billion run rate. The company also reported positive operating cash flow during the year, underlining its financial momentum.
The new funding will support further expansion across key international markets, including Europe, the Gulf region, Latin America and Asia, as well as continued growth in the United States.
To support this expansion, WHOOP plans to hire more than 600 additional employees globally, focusing on research, development and product innovation.
The involvement of established healthcare organisations such as Abbott signals a broader shift towards integrating consumer technology with clinical expertise.
By combining wearable technology with advanced analytics, WHOOP aims to provide a more holistic view of health, enabling users to make informed decisions about their lifestyle and potentially prevent serious conditions before they develop.
The platform’s high engagement levels, with users opening the app multiple times per day, highlight the growing demand for real-time health insights that go beyond traditional fitness tracking.
While WHOOP initially gained traction among athletes and high-performance individuals, the company is now targeting a broader audience, including executives, professionals and consumers seeking to optimise both health and productivity.
The focus is increasingly on “healthspan”, the length of time individuals remain healthy and active, rather than simply lifespan.
Cristiano Ronaldo, an investor and ambassador, described the platform as a key tool in managing his own health, reflecting its positioning at the intersection of performance and wellbeing.
The latest funding round reinforces WHOOP’s position as one of the most valuable players in the rapidly expanding digital health sector.
As advances in AI and data analytics continue to reshape healthcare, companies that can combine technology, user engagement and clinical relevance are expected to play a central role in the future of the industry.
For WHOOP, the challenge now is to scale its platform globally while maintaining accuracy, trust and regulatory compliance, transforming wearable data into meaningful, actionable health outcomes at scale.
Read more:
WHOOP raises $575m at $10bn valuation to scale global health platform
